1000063-82-0Relevant academic research and scientific papers
THERAPEUTIC COMPOUNDS
-
Paragraph 0129; 0130, (2018/07/06)
no abstract published
Macrocyclic Compounds as Antiviral Agents
-
, (2009/12/27)
The present invention relates to macrocyclic compounds of formula (I): wherein W, n, m, R1, R2, R3, R4, R5, Ra, M, Z and ring B are defined herein, and pharmaceutically acceptable salts the
Bismacrocyclic inhibitors of hepatitis C NS3/4a protease
McCauley, John A.,Rudd, Michael T.,Nguyen, Kevin T.,McIntyre, Charles J.,Romano, Joseph J.,Bush, Kimberly J.,Varga, Sandor L.,Ross III, Charles W.,Carroll, Steven S.,DiMuzio, Jillian,Stahlhut, Mark W.,Olsen, David B.,Lyle, Terry A.,Vacca, Joseph P.,Liverton, Nigel J.
supporting information; experimental part, p. 9104 - 9107 (2009/02/08)
(Chemical Equation Presented) Double time: The bismacrocycle 2 was prepared from 1 by a selective double ring-closing metathesis (RCM) reaction to form the 18- and 15-membered rings simultaneously. Derivative 3 shows excellent potency against NS3/4a protease.
HCV NS3 PROTEASE INHIBITORS
-
Page/Page column 40-41, (2008/12/05)
The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
